CAR therapies
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Hemogenyx to Use FLT3 Assay to Identify AML Patients for CAR T-Cell Trial
The firm expects to launch its Phase I trial of HEMO-CAR-T in FLT3-expressing AML patients at MD Anderson Cancer Center imminently.
Arsenal Biosciences Raises $325M in Series C Financing Round
The firm will use the funds to continue developing its pipeline of CAR T-cell therapies, scale up manufacturing capabilities, and explore novel T-cell therapies.
First Patient Dosed in Phase I Trial of Cartesian Therapeutics' Anti-BCMA mRNA CAR T-Cell Therapy
The trial will examine the safety and tolerability of Descartes-15 in patients with relapsed or refractory multiple myeloma.
Orgenesis Advancing CD19 CAR T-Cell Therapy Into Phase I/II Leukemia Trial
The firm made the decision based on real-world data showing adults and children had high complete response and low cytokine release syndrome rates to ORG-101.